National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Alectinib (Alecensa ®) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib.

NCPE Assessment Process
Rapid review commissioned 03/01/2017
Rapid review completed 27/02/2017
Rapid Review outcome Full pharmacoeconomic evaluation recommended at the submitted price.
The HSE has approved reimbursement following confidential price negotiations October 2017.

 

Alectinib (Alecensa ®) for the first-line treatment of adult patients with ALK+ advanced NSCLC

NCPE Assessment Process
Rapid review commissioned 08/11/2017
Rapid review completed 04/12/2017
Rapid Review outcome Full pharmacoeconomic evaluation recommended
HTA commissioned by the HSE 20/12/2017
Pre-submission consultation with Applicant 13/02/2018
Submission received from Applicant 25/04/2018
Preliminary review sent to Applicant 15/10/2018
NCPE assessment re-commenced 30/10/2018
Factual accuracy sent to Applicant 05/12/2018
NCPE assessment re-commenced 19/12/2018
NCPE assessment completed 15/01/2019
NCPE assessment outcome Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Summary